PACRITINIB vs PAZOPANIB

Compare PACRITINIB (Vonjo) and PAZOPANIB (Pazopanib) — clinical data, side effects, and patient experiences.

PACRITINIB

Vonjo · Targeted Cancer Therapy

How it works

12.1 Mechanism of Action Pacritinib is an oral kinase inhibitor with activity against wild type Janus associated kinase 2 (JAK2), mutant JAK2V617F, FMS-like tyrosine kinase 3 (FLT3...

Approved for

See full prescribing information

OralTablet

PAZOPANIB

Pazopanib · Targeted Cancer Therapy

How it works

12.1 Mechanism of Action Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor r...

Approved for

See full prescribing information

OralTablet

Quick Comparison

PACRITINIBPAZOPANIB

Drug Class

Targeted Cancer Therapy

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

PACRITINIB

Diarrhea

>10%

Fatigue

>10%

Nausea

1-10%

Weakness

0.1-1%

Drug Not Working

0.1-1%

Dizziness

0.1-1%

Shortness of Breath

0.1-1%

Constipation

0.1-1%

PAZOPANIB

Diarrhea

>10%

Fatigue

1-10%

Nausea

1-10%

Drug Not Working

1-10%

Decreased Appetite

1-10%

Vomiting

1-10%

High Blood Pressure

0.1-1%

Weakness

0.1-1%

FDA Warnings

PACRITINIB

5 WARNINGS AND PRECAUTIONS Hemorrhage: Avoid use in patients with active bleeding and hold VONJO prior to any planned surgical procedures
Major Adverse Cardiac Events (MACE): Risk may be increased in current/past smokers and patients with other cardiovascular risk factors
Past/current smokers may be at increased risk ( 5
Risk of Infection: Delay starting VONJO until active serious infections have resolved

PAZOPANIB

5 WARNINGS AND PRECAUTIONS Hepatic Toxicity: Severe and fatal hepatotoxicity has occurred
1 ) QT Prolongation and Torsades de Pointes: Monitor patients who are at significant risk of developing QT interval prolongation
Conduct baseline and periodic evaluation of LVEF in patients at risk of cardiac dysfunction
3 ) Hemorrhagic Events: Fatal hemorrhagic events have occurred

Clinical Trial Data

No head-to-head clinical studies found for PACRITINIB vs PAZOPANIB.

PACRITINIB vs PAZOPANIB: What You Should Know

Key Differences

Both PACRITINIB and PAZOPANIB belong to the Targeted Cancer Therapy class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Shared Indications

Both medications are approved for See full prescribing information. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.

Safety Considerations

PACRITINIB carries 4 FDA warnings. PAZOPANIB carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

LORLATINIB vs PAZOPANIB→PAZOPANIB vs SORAFENIB→GEFITINIB vs PAZOPANIB→LAROTRECTINIB vs PAZOPANIB→IBRUTINIB vs PAZOPANIB→BRIGATINIB vs PAZOPANIB→

Loading comparison data...

PACRITINIB vs PAZOPANIB

Compare PACRITINIB (Vonjo) and PAZOPANIB (Pazopanib) — clinical data, side effects, and patient experiences.

PACRITINIB

Vonjo · Targeted Cancer Therapy

How it works

12.1 Mechanism of Action Pacritinib is an oral kinase inhibitor with activity against wild type Janus associated kinase 2 (JAK2), mutant JAK2V617F, FMS-like tyrosine kinase 3 (FLT3...

Approved for

See full prescribing information

OralTablet

PAZOPANIB

Pazopanib · Targeted Cancer Therapy

How it works

12.1 Mechanism of Action Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor r...

Approved for

See full prescribing information

OralTablet

Quick Comparison

PACRITINIBPAZOPANIB

Drug Class

Targeted Cancer Therapy

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

PACRITINIB

Diarrhea

>10%

Fatigue

>10%

Nausea

1-10%

Weakness

0.1-1%

Drug Not Working

0.1-1%

Dizziness

0.1-1%

Shortness of Breath

0.1-1%

Constipation

0.1-1%

PAZOPANIB

Diarrhea

>10%

Fatigue

1-10%

Nausea

1-10%

Drug Not Working

1-10%

Decreased Appetite

1-10%

Vomiting

1-10%

High Blood Pressure

0.1-1%

Weakness

0.1-1%

FDA Warnings

PACRITINIB

5 WARNINGS AND PRECAUTIONS Hemorrhage: Avoid use in patients with active bleeding and hold VONJO prior to any planned surgical procedures
Major Adverse Cardiac Events (MACE): Risk may be increased in current/past smokers and patients with other cardiovascular risk factors
Past/current smokers may be at increased risk ( 5
Risk of Infection: Delay starting VONJO until active serious infections have resolved

PAZOPANIB

5 WARNINGS AND PRECAUTIONS Hepatic Toxicity: Severe and fatal hepatotoxicity has occurred
1 ) QT Prolongation and Torsades de Pointes: Monitor patients who are at significant risk of developing QT interval prolongation
Conduct baseline and periodic evaluation of LVEF in patients at risk of cardiac dysfunction
3 ) Hemorrhagic Events: Fatal hemorrhagic events have occurred

Clinical Trial Data

No head-to-head clinical studies found for PACRITINIB vs PAZOPANIB.

PACRITINIB vs PAZOPANIB: What You Should Know

Key Differences

Shared Indications

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.